OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2024-03-31-accounts

Registered charity number: 1185148

Report of the Trustees and Unaudited Financial Statements for the year ended 31 March 2024

for British Lymphology Society CIO

British Lymphology Society CIO Contents of the Financial Statements for the year ended 31 March 2024

Page
Information page 1
Report of the Trustees 2
Independent Examiner's Report 7
Statement of Financial Activities 8
Balance Sheet 9
Notes to the Financial Statements 10

British Lymphology Society CIO Information Page for the year ended 31 March 2024

Registered Charity Number

1185148

Trustees

Chairperson - Margaret Sneddon Co Vice Chairperson - Yolande Borthwick (from November 2023) Co Vice Chairperson - Lorraine Brown (from November 2023) Co Vice Chairperson - Katie Riches (resigned November 2023) Treasurer - Peter Hooper-Smith

Trustees - Rebecca Elwell Rachael Hutton Devina Dicarlo Tamara Kosevic Carla Zanichelli Vives (appointed November 2023) Catriona O'Neill (resigned November 2023) Jane Board (resigned November 2023) Jenny Furniss (resigned December 2023) Fran Campbell (resigned November 2023) Rhian Noble Jones (resigned November 2023)

Co-opted Trustee

Cheryl White

BLS Scientific Committee chair

Emma Underwood (appointed November 2023)

Independent Examiner

J Bardolph FCCA Accountably Ltd 1st Floor, Unit 12 Compass Point Ensign Way Hamble Southampton Hampshire SO31 4RA

1

British Lymphology Society CIO Report of the Trustees for the year ended 31 March 2024

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity registered with the Charity Commission on 3 September 2019, under registration number 1185148 and is a charitable incorporated organisation - CIO.

Risk management

Proactive risk identification through regular risk assessments with key stakeholders and project leads means that we systematically map potential risks across the Charity, including financial, operation, regulatory and reputational. Once risks are identified, we assess their potential impact and likelihood as per the Charity Commission’s Risk Management Framework (CC26). This has included strengthening our financial controls, and data and cyber security. Our risk management procedure includes the methodical reporting of incidents that occur. During the last year, the BLS has experienced two incidents from different external sources. Our process of reporting has also enabled our testing and subsequent amendment of the BLS’s investigation form to enhance the description of the event and clarity of the action(s) taken to mitigate risk.

OBJECTIVES AND ACTIVITIES FOR THE PUBLIC BENEFIT

The preservation and protection of good health among people in the United Kingdom living with lymphoedema/chronic oedema in particular by:

We develop resources to inform, educate and guide clinical practice. We also seek to use our unique professional leadership position and expertise of our Members to advise government, NHS and other professional bodies and organisations and work with other stakeholders, to raise awareness.

Strategic Priorities

There is much that the Society wishes to achieve. Within the context of the pandemic, we agreed the following priorities for the Charity:

To reach these aims, we have an annual delivery plan, which sets out key projects and work streams to deliver measurable outcomes for the Charity, and those we seek to support.

The trustees confirm that they have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the Charity's aims and objectives and in planning future activities.

ACHIEVEMENTS AND PERFORMANCE

As we reflect on another year of progress and growth, I am pleased to welcome you to our annual report. This report reflects the collective efforts of everyone involved, from our trustees and staff to our dedicated members and partners. Together, we've made great strides in tackling some big projects, and I hope you'll find this report both informative and inspiring as we look back on our achievements and ahead to the future. It has been an exceptionally busy year! We have begun our website and membership project, which will see a new BLS site that is easy to navigate and make managing your membership even easier. We have also started the rebrand project which is really exciting.

2

British Lymphology Society CIO Report of the Trustees for the year ended 31 March 2024

October 2023

The biggest event in our calendar is our annual conference held every October. It was a pleasure to welcome delegates of the BLS conference to a new venue this year, Chester Racecourse. The new venue gave us the opportunity to add more variation to the conference programme, which meant that delegates could build their own agenda and chose the education sessions most relevant to them. Well over 200 delegates and more than 100 exhibitors took part in a new conference format. Before the full day of scientific content, we held a day of workshops and concurrent education sessions, speed sessions with our coalition partners and other specialists, and events run by our corporate partners. The scientific programme was full of new guidance and emerging research.

A huge highlight was welcoming Professor Stanley Rockson from Stanford University, to speak on his research and take part in a live Q&A. It is a pleasure to welcome internationally recognised speakers to our conference and bring learning from other leading researchers around the world. Thanks to our strong relationship with the international Lymphedema Education & Research Network (LE&RN) based in the US, we were also joined by Hollywood stars! Actors Kathy Bates and Steve Guttenberg recorded personalised messages for the BLS delegates, talking about their own experiences of lymphoedema and the challenges they and their families have faced. Thank you to everyone who came, to our sponsors and everyone else who made it possible. We are looking forward to returning in 2024.

November 2023

We held our Annual General Meeting and updated our constitution.

February 2024

National Lymphoedema Conference, now a very successful annual event on which we work in partnership with the Mark Allen Publishing Group and Lipoedema UK to run and for which we develop the annual programme.

March 2024

We attended Wound Care Today, a huge annual 2-day event which enables us to engage with large numbers of community nursing staff, a healthy number of whom register to receive ongoing information from the BLS to extend their knowledge.

Lymphoedema Awareness Week and World Lymphoedema Day, we had a great start to 2024 with the excitement and run up to the annual Lymphoedema Awareness Week in March. This year, the BLS ran a series of free webinars with support from our partners and Members, focussing on lymphoedema in children and young people, and primary lymphoedema. We were joined by specialists in the UK and children and young people with lymphoedema, including the Tierney family who gave moving interviews with their children. We received free publicity and press enquiries thanks to our Patron Trisha Goddard, who had us join her radio show during the week, where she interviewed Team GB Para Olympian Didi Okoh. Plans are well under way for the 2025 Lymphoedema Awareness Week!

May 2024

The Primary Care Show, a huge, busy 3-day event attended by all Members of primary care teams, providing a unique opportunity to engage with general practitioners, physiotherapists, podiatrists and all other disciplines and their various branches.

We were honoured to attend a reception hosted by Gemma Levine in aid of the Lymphoedema Research Fund. Speakers and guests of honour included Dame Judi Dench, Simon Callow CBE and Dame Joanna Lumley.

The BLS part-funded a member to attend the Australian Lymphoedema Conference and we look forward to welcoming their members to BLS2024.

The BLS Board Strategy Day - This is an important day where the BLS trustees and staff come together to make plans for the following year. There are lots of exciting projects this year and we can’t wait to tell you more about them as they progress.

We presented at the Scottish Leg Ulcer Forum, attended by 100 community-based nurses.

3

British Lymphology Society CIO Report of the Trustees for the year ended 31 March 2024

June 2024

Legs Matter Week - We continue to champion this campaign, highlighting the harm experienced by patients when their lower limb problems are either not recognised, taken seriously or appropriately followed up. Looking ahead to September, we will be both presenting and exhibiting at the Lindsay Leg Club Foundation Conference, providing yet another opportunity to meet with another audience of health care practitioners.

New Resources

The BLS is constantly working on initiatives and resource to either raise awareness of lymphoedema, enhance healthcare professional knowledge or support good clinical practice. This year we were delighted to launch the Lower Limb inflammatory Pathway, which updates the Red Leg Pathway, covering all skin tones and includes the Charcot Foot. We have worked with patient organisations to produce resources for patients for the first time. Thank you to the Lymphoedema Support Network, Lymph-What-Oedema and Lymphoedema United for your continued hard work and support in this project.

Resources in Development

We are looking forward to the launch of new documents that we have been working hard to develop this year. Delegates attending the BLS conference will be the first to see the MLD Position Document, the updated Vascular Assessment document, the BLS Heart Failure document and a document on compression guidance that we have worked on with the publishers Omniamed.

The events, campaigns, and resources you see are the most visible aspects of our work at BLS, but there is so much more that happens behind the scenes. We are a learning organisation, unafraid to embrace change and constantly exploring more effective, efficient, and cost-conscious ways to fulfil our mission. The skills of our Board of Trustees have become more diverse, which has only strengthened our ability to govern with better insight. We have worked diligently to ensure that all our efforts continue to be underpinned by strong governance, financial security, and robust systems and processes. This foundation ensures that BLS is wellpositioned for a strong future and continued success in achieving our charitable aims. The achievements we celebrate and the plans we set forth as a Society are made possible only through the passion, commitment, and teamwork of our trustees, contracted staff, dedicated members, and corporate partners. We extend our heartfelt thanks to everyone who contributes to our successes as we work towards earlier recognition, prompt and appropriate intervention, and improved treatment outcomes. Please continue to support the work of the Charity, and together, we can make an even greater impact.

THE FUTURE

Lymphoedema Awareness Week 2025

Following the success of the last three year's awareness weeks, we plan to deliver more educational webinars and Q&A sessions online. This year, we will be continuing the theme of our 2024 conference by focussing some of our sessions on cancer related lymphoedema, speaking to specialists in the field and hearing from patients. We are very excited about the educational events already planned, and we will be live on air again with our patron Trisha Goddard. If you have any plans for Lymphoedema Awareness Week, be sure to let us know so that we can share them with our Members and Friends.

Conference 2025

We are already planning the 2025 conference, building on the successes and lessons of previous years. We'll see more international speakers as well as home-grown talent, and there will be more opportunities for interactive learning and networking. 40th Anniversary next year marks BLS’s 40th anniversary and plans are afoot to celebrate this with as many members as we can. Keep an eye on News and Views and our regular member bulletins to find out more.

4

British Lymphology Society CIO Report of the Trustees for the year ended 31 March 2024

Strategic Objectives

The Board have developed new strategic objectives for the next three years, and we are looking forward to delivering them with all of our members:

SCIENTIFIC COMMITTEE (BLSSC) REPORT

During 2023/24 the Scientific Committee (SC) met online to continue to support the BLS Board with the overall aim of promoting research and service development in the field of lymphoedema in the UK.

BLS Conference 2023 - Scoring of both the oral and poster presentations at the annual BLS conference.

BLS Conference 2024 – The SC have reviewed the marking criteria for abstract submissions to further ensure that the scientific content of the BLS conference is robust. The SC continue to manage the abstract submission process and anonymous peer review selection process for the 2024 conference. This year attracting 26 submissions.

The Lymphoedema Research Development Grant (LRDG) has been renamed to reflect a broader range of research development opportunities that it can support. It offers awards of up to £10,000 to BLS members to develop their skills in research and evidence implementation and further research into lymphoedema in the UK. The aim was to widen the scope for applicants to include projects which may not need REC approval, but which use research methods (e.g. large service development projects and audits) as long as the outputs are agreed to align with the charity’s objectives.

The LRDG was relaunched at BLS conference 2023 with applications open from January 2024. There was one application and the full £10,000 has been awarded to David Florentin for his study: A mixed methods study to determine the prevalence of lymphoedema and related conditions in Wales by ethnicity, and to understand how to deliver equitable lymphoedema services to meet these needs (on receipt of ethical approval).

The Case Report Competition continues to develop, with more submissions each year. We received 5 applications this year and awarded the prize to Jesús González Rubiño. Jesús will be supported to publish the case report in the Chronic Oedema Supplement.

News & Views - SC members continue to contribute articles for each newsletter on a range of research and clinical evidence publication topics. Clinical Queries - BLSSC members have regularly provided or signposted to, scientific or clinical advice when are submitted to BLS.

The numbers of clinical queries are increasing each year. These are managed anonymously, and a generic response is placed in the FAQ section of the BLS website for wider learning.

Clinical advisors to external bodies - BLSSC members also volunteer their time as clinical experts and advisors to bodies such as NICE when clinical reviews relevant to Lymphoedema are being conducted or when national/international guidelines are being created.

Contributing to specific BLS workstreams - Members of the SC have been part of specific working subgroups of the Board developing BLS Factsheets and developing a guidance document on MLD. BLSSC Membership - There were no vacancies in the current period for the BLSSC, in order to increase our membership, we coopted Beccy Elwell in her position as conference organiser and will therefore be advertising three positions from October 2024 including an honorary position.

Administration and governance - The BLSSC has tried to streamline processes over the last year and agree annual dates for workstreams to make more efficient use of the admin teams time and also to be more consistent with dates allowing applicants to plan submissions. In relation to governance, the BLSSC is subject to the same procedures as the main Board and has been working with the Board to align GDPR and other legal requirements.

5

British Lymphology Society CIO Report of the Trustees for the year ended 31 March 2024

FINANCIAL REVIEW AND RESERVES POLICY

The BLS continues to sustain its progress towards financial stability. The success of the BLS conference and careful control of expenditure means that we have maintained a solid financial position through diligent planning and prudent budget management. The BLS has added to its reserves in the financial year 2023/4, some of which will be invested in significant projects for the Charity in the coming year.

The relevant income, expenditure, cash and results for the year are shown under Unrestricted Funds. During the year the charity received income of £226,102, incurred costs of £218,046 resulting in a surplus of £8,056.

The policy of the charity to maintain unrestricted funds which have not been designated for a specific use of twelve months’ expenditure. The policy ensures that reserves at this level will be sufficient so that in the event of a significant drop in funding, that the trustees will be able to continue the charity’s activities while consideration is given to ways in which additional funds may be raised. The twelve months’ expenditure level of reserves was achieved throughout the financial year.

INDEPENDENT EXAMINER

Jonathan Bardolph FCCA has been re-appointed as independent examiner for the ensuing year.

Approved by order of the board of trustees on………………………… 30 Sep 2024 and signed on its behalf by:

M Sneddon

…………………………….

Margaret Sneddon - Chairperson

6

British Lymphology Society CIO Independent Examiner's Report to the Trustees for the year ended 31 March 2024

I report to the trustees on my examination of the accounts of the above charity for the year ended 31 March 2024.

Responsibilities and basis of report

As the charity's trustees you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ("the Act").

I report in respect of my examination of the charity's accounts as carried out under section 145 of the 2011 Act and in carrying out my examination, I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination which gives me cause to believe that in, any material respect:

  1. the accounting records were not kept in accordance with section 130 the Charities Act; or

  2. the accounts did not accord with the accounting records; or

  3. the accounts did not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a "true and fair" view which is not a matter considered as part of an independent examination

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Jonathan Bardolph

………….………. J Bardolph FCCA Independent Examiner

Accountably Ltd 1st Floor, Unit 12 Compass Point Ensign Way Hamble Southampton Hampshire SO31 4RA

01 Oct 2024

…………….……..

7

British Lymphology Society CIO Statement of Financial Activities for the year ended 31 March 2024

Notes
INCOMING RESOURCES
Incoming resources from generated funds
Voluntary income
2
Charitable activities
3
Investment income
4
Total incoming resources
RESOURCES EXPENDED
Charitable activities
5
Governance costs
6
Total resources expended
Net movement in funds
RECONCILIATION OF FUNDS
Total funds brought forward
9
TOTAL FUNDS CARRIED FORWARD
9
NET INCOMING RESOURCES and net
income for the year		 2024
Unrestricted
fund
Restricted
fund
Total funds
£
£
£
58,283
-
58,283
161,624
-
161,624
5,936
259
6,195
225,843
259
226,102
212,271
-
212,271
5,775
-
5,775
218,046
-
218,046
7,797
259
8,056
7,797
259
8,056
259,266
22,402
281,668
267,063
22,661
289,724		 2023
Total funds
£
54,975
162,967
1,501
219,443
170,796
3,611
174,407
45,036
45,036
236,632
281,668

The Statement of Financial Activities includes all gains and losses in the year and therefore a statement of total recognised gains and losses has not been prepared.

All of the above amounts relate to continuing activities.

The notes form part of these financial statements.

8

British Lymphology Society CIO
Balance Sheet
as at 31 March 2024
Notes
CURRENT ASSETS
Debtors
7
Cash at bank
CREDITORS
Amounts falling due within one
year
8
NET CURRENT ASSETS
NET ASSETS
FUNDS
9
Unrestricted funds:
Restricted funds
TOTAL FUNDS		 2024
Total funds
£
49,021
379,230
428,251
(138,527)
289,724
289,724
267,063
22,661
289,724		 2023
Total funds
£
32,364
405,433
437,797
(156,129)
281,668
281,668
259,266
22,402
281,668		 2023
Total funds
£
32,364
405,433
437,797
(156,129)
281,668
281,668
259,266
22,402
281,668
281,668
259,266
22,402
281,668

30 Sep 2024

The financial statements were approved by the Board of Trustees on ……………………..…... and were signed on its behalf by:

M Sneddon

………………………………… ……………………………..

Chairperson - Margaret Sneddon

Treasurer - Peter Hooper-Smith

The notes form part of these financial statements.

9

British Lymphology Society CIO Notes to the Financial Statements

for the year ended 31 March 2024

1 ACCOUNTING POLICIES

(a) Basis of preparation of the accounts

The accounts have been prepared under the historical cost convention with items recognised at cost or transaction value unless otherwise stated in the relevant notes to the accounts. The accounts have been prepared in accordance with the Statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) effective January 2019.

(b) Funds

General funds represent the funds of the charity that are not subject to any restrictions regarding their use and are available for application for general purposes. Funds designated for a particular purpose by the charity are also unrestricted. Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Donations, legacies and other forms of voluntary income are recognised as incoming resources when receivable, except in so far as they are incapable of financial measurement.

Trading income is shown net of related expenses as this better reflects the contribution of these activities to the charity.

Income tax recoverable in relation to donations received under Gift Aid is recognised at the time of the donation.

Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Fundraising costs are those incurred in seeking voluntary contributions and do not include the costs of disseminating information in support of the charitable activities. Support costs are those costs incurred directly in support of expenditure on the objects of the charity. Governance costs are those associated with the governance arrangements of the charity.

(e) Taxation

The charity is exempt from corporation tax on its charitable activities.

2
VOLUNTARY INCOME
Membership subscriptions		 Unrestricted
funds
£
58,283
58,283		 Restricted
funds
£
-
-		 Total
funds
2024
£
58,283
58,283		 Total funds
2023
£
54,975
54,975

10

British Lymphology Society CIO Notes to the Financial Statements

for the year ended 31 March 2024

3
CHARITABLE ACTIVITIES
Conference
Advertising and other services
4
INVESTMENT INCOME
Interest receivable
5
EXPENDITURE - Charitable activities
Professional fees
Office and administration costs
Website, computer and internet costs
Newsletter
Conference
Promotional items and surveys
Wages and expenses		 Unrestricted
funds
£
147,588
14,036
161,624
Unrestricted
funds
£
5,936
Unrestricted
funds
£
-
52,871
5,282
5,200
98,868
25,620
24,430
212,271		 Restricted
funds
£
-
-
-
Restricted
funds
£
259
Restricted
funds
£
-
-
-
-
-
-
-
-		 Total
funds
2024
£
147,588
14,036
161,624
Total
funds
2024
£
6,195
Total
funds
2024
£
-
52,871
5,282
5,200
98,868
25,620
24,430
212,271		 Total funds
2023
£
144,460
18,507
162,967
Total funds
2023
£
1,501
Total funds
2023
£
718
51,345
3,527
4,986
85,500
3,648
21,072
170,796

11

British Lymphology Society CIO Notes to the Financial Statements

for the year ended 31 March 2024

6 EXPENDITURE - Governance costs

6
EXPENDITURE - Governance costs
Unrestricted
Restricted
funds
funds
£
£
Book-keeping
499
-
Independent examiner
1,740
-
Insurance
1,359
-
Committee meetings
2,025
-
Exchange differences
152
-
5,775
-
7
DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
Trade debtors
Other debtors
8
CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
Trade creditors
Deferred income
Accrued charges
9
MOVEMENT ON UNRESTRICTED AND RESTRICTED FUNDS
Balance at 1
April
Incoming
Outgoing
2023
resources
resources
£
£
£
Unrestricted
General fund
259,266
225,843
(218,046)
Restricted fund:
Scientific research
22,402
259
-
281,668
226,102
(218,046)		 Total
funds
2024
£
499
1,740
1,359
2,025
152
5,775
2024
£
27,245
21,776
49,021
2024
£
9,607
124,874
4,046
138,527
Transfers
between
funds
£
-
-
-		 Total funds
2023
£
916
1,650
883
162
-
3,611
2023
£
4,096
28,268
32,364
2023
£
7,604
145,118
3,407
156,129
Balance at
31 March
2024
£
267,063
22,661
289,724

12

British Lymphology Society CIO Notes to the Financial Statements for the year ended 31 March 2024

10 ANALYSIS OF NET ASSETS BETWEEN FUNDS
Unrestricted:
General fund
Restricted:
Scientific research		 Tangible fixed
assets
£
-
-
-		 Net
current
assets
£
267,063
22,661
289,724		 Total
£
267,063
22,661
289,724

11 OTHER BENEFITS RECEIVED BY THE CHARITY

We are grateful to our corporate members for their generosity and their support in the 2023 conference. In addition, thank you to all who sponsor us in formal and informal ways.

12 TRUSTEES REMUNERATION AND EXPENSES

The following trustees received reimbursement of expenses during the year:

£
K Riches 92.00
M Sneddon 455.00
R Noble-Jones 216.00
C O'Neill 109.00
R Elwell 185.00
L Brown 245.00
J Board 375.00
C White 1,837.00
Y Borthwick 60.00
P Hooper-Smith 968.00
F Campbell 176.00

No trustee nor anyone connected with them received any remuneration during the period in respect of their services as trustees.

13

Issuer

Accountably Ltd

Document generated Wed, 25th Sep 2024 12:37:16 BST

Document fingerprint b09487c935939a0e1dd460e71b622df3

Parties involved with this document

Document processed

Party + Fingerprint

Fri, 27th Sep 2024 9:14:41 BST Mon, 30th Sep 2024 16:15:25 BST Mon, 30th Sep 2024 16:15:26 BST

Mr Peter Hooper-Smith - Signer (d3e93f60cef2643a26739b3e48896b04) Mrs Margaret Sneddon - Signer (90c4b0ccbeff061ac18ad444ee74b2d3) Kirsty Lovett - Copied In (914ff97671fe15f37e0c396a4cb4335b)

Audit history log

Date

Action

Mon, 30th Sep 2024 16:15:26 BST Mon, 30th Sep 2024 16:15:26 BST Mon, 30th Sep 2024 16:15:26 BST Mon, 30th Sep 2024 16:15:26 BST Mon, 30th Sep 2024 16:15:25 BST Mon, 30th Sep 2024 16:07:21 BST Fri, 27th Sep 2024 9:15:02 BST Fri, 27th Sep 2024 9:14:43 BST Fri, 27th Sep 2024 9:14:42 BST Fri, 27th Sep 2024 9:14:42 BST Fri, 27th Sep 2024 9:14:41 BST Fri, 27th Sep 2024 9:00:33 BST Wed, 25th Sep 2024 12:37:22 BST Wed, 25th Sep 2024 12:37:22 BST Wed, 25th Sep 2024 12:37:22 BST Wed, 25th Sep 2024 12:37:16 BST Wed, 25th Sep 2024 12:37:16 BST

Wed, 25th Sep 2024 12:37:16 BST

Mrs Margaret Sneddon viewed the envelope (82.33.15.35) Document emailed to party email (18.133.225.106) This envelope has been signed by all parties (82.33.15.35) Sent the envelope to Kirsty Lovett for signing (82.33.15.35) Mrs Margaret Sneddon signed the envelope (82.33.15.35) Mrs Margaret Sneddon viewed the envelope (82.33.15.35) Mr Peter Hooper-Smith viewed the envelope (90.210.196.42) Mr Peter Hooper-Smith viewed the envelope (90.210.196.42) Sent the envelope to Mrs Margaret Sneddon for signing (90.210.196.42) Document emailed to party email (18.169.191.107) Mr Peter Hooper-Smith signed the envelope (90.210.196.42) Mr Peter Hooper-Smith viewed the envelope (90.210.196.42) Document emailed to party email (35.176.94.23) Sent the envelope to Mr Peter Hooper-Smith for signing () Envelope generated ()

Kirsty Lovett has been assigned to this envelope. (18.133.63.166) Mrs Margaret Sneddon has been assigned to this envelope. (18.133.63.166)

Mr Peter Hooper-Smith has been assigned to this envelope. (18.133.63.166)

Wed, 25th Sep 2024 12:37:16 BST Document generated with fingerprint b09487c935939a0e1dd460e71b622df3. (18.133.63.166) Wed, 25th Sep 2024 12:37:16 BST Envelope generated with fingerprint 18d584cf9df5732d1c98b71c04a604c0 (18.133.63.166)

Issuer Accountably Ltd Document generated Tue, 1st Oct 2024 9:07:14 BST Document fingerprint 3e28f4587f203ce9c73015917f6e8d34

Parties involved with this document

Document processed Party + Fingerprint Tue, 1st Oct 2024 12:38:53 BST Jonathan Bardolph - Signer (51cfbfb4501caff04af29a8afc8965e4) Tue, 1st Oct 2024 12:38:53 BST Kirsty Lovett - Copied In (d9eb388ae695d535d60f2a38de067541) Audit history log Date Action Tue, 1st Oct 2024 12:38:54 BST Jonathan Bardolph viewed the envelope (51.195.195.129) Tue, 1st Oct 2024 12:38:54 BST Document emailed to party email (18.132.245.80) Tue, 1st Oct 2024 12:38:53 BST This envelope has been signed by all parties (51.195.195.129) Tue, 1st Oct 2024 12:38:53 BST Sent the envelope to Kirsty Lovett for signing (51.195.195.129) Tue, 1st Oct 2024 12:38:53 BST Jonathan Bardolph signed the envelope (51.195.195.129) Tue, 1st Oct 2024 12:37:56 BST Jonathan Bardolph viewed the envelope (51.195.195.129) Tue, 1st Oct 2024 9:07:21 BST Document emailed to party email (35.176.126.224) Tue, 1st Oct 2024 9:07:21 BST Sent the envelope to Jonathan Bardolph for signing () Tue, 1st Oct 2024 9:07:21 BST Envelope generated () Tue, 1st Oct 2024 9:07:14 BST Envelope has been set to automatically remind the active signer every 2 day(s). (35.176.231.177) Tue, 1st Oct 2024 9:07:14 BST Kirsty Lovett has been assigned to this envelope. (35.176.231.177) Tue, 1st Oct 2024 9:07:14 BST Jonathan Bardolph has been assigned to this envelope. (35.176.231.177) Tue, 1st Oct 2024 9:07:14 BST Document generated with fingerprint 3e28f4587f203ce9c73015917f6e8d34. (35.176.231.177) Tue, 1st Oct 2024 9:07:14 BST Envelope generated with fingerprint 53b409724a70d7f03270f3c8548c676e (35.176.231.177)